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Abstract
This article provides an overview of different neurointerventional procedures 
by reviewing important papers relevant to neurovascular disease and the 
latest concept of endovascular treatment. The focus was on studies that 
dealt with cerebral aneurysm, arteriovenous malformation, direct carotid-
cavernous fistula, dural arteriovenous fistula, intracranial atherosclero-
sis, and acute symptomatic intracranial arterial occlusion. Studies on 
extracranial atherosclerosis and other nonvascular part were excluded. 
Interventional neuroradiology is a well-developed subspecialty that mainly 
treats neurovascular disease in a less invasive way. Advances in new tech-
nology and knowledge will make it an important method to treat different 
disorders in future. [Tzu Chi Med J 2008;20(3):177–187]
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Interventional neuroradiology is one of the latest well-
developed subspecialties that focus on treatment of 
disorders of the nervous system and related issues. 
It is also known as endovascular neurosurgery, intra-
vascular neurosurgery, and interventional and thera-
peutic neuroradiology (ITN). Worldwide, two of the 
largest organizations in this field are the World 
Federation of ITN (WFITN) and the American Society of 
ITN (ASITN). However, during the 4th annual meeting 
of the ASITN from July 30 to August 3, 2007, the 
society decided to change their name to the Society 
of Neuro-Interventional Surgery (SNIS).
Over the last 20 years, interventional neuroradiol-
ogy has been a less invasive modality compared to 
open neurosurgery for the treatment of a wide range 
of neurovascular disorders. Refinements in technique, 
advances in knowledge of neurovascular anatomy, and 
improvements in the design of microcatheters, 
guidewires and embolic materials, as well as the pro-
duction of high quality X-ray fluoroscopic systems, 
have yielded superior clinical outcomes and provided 
an impetus to treat more often using interventional 
neuroradiology. The dramatic evolution of interven-
tional neuroradiology has secured its primary role in 
the treatment of many vascular lesions, such as intrac-
ranial aneurysms, painful compression fractures of 
vertebrae, dural and venous sinus thromboses, some 
arteriovenous malformations, post-traumatic bleeding 
and fistulae, and many dural arteriovenous fistulae. 
It is also an effective alternative to surgery in those 
with premorbid medical conditions such as extracra-
nial and intracranial atherosclerotic diseases, and is 
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a valuable adjunct to neurosurgery or other thera-
pies in the treatment of arteriovenous malformations, 
some complex giant aneurysms and skull base tumors. 
We can foresee that, in the near future, interventional 
neuroradiology will increasingly play an important role 
in the management of acute ischemic stroke and 
intracerebral hemorrhage (ICH). In this review, well-
developed endovascular treatment will be discussed.
2. Cerebral aneurysms
Surgical clipping or endovascular coiling are the two 
major methods of treatment for cerebral aneurysms. 
There is much controversy about the pros and cons 
of both treatments. However, after the two publica-
tions of the International Subarachnoid Aneurysm Trial 
(ISAT) [1,2], the concept of intracranial aneurysm 
treatment was at least clarified in some basic terms. 
In these two papers, neurosurgery was compared 
with endovascular treatment of ruptured aneurysms, 
and a 24% relative and 7.4% absolute reduction in 
death or dependency at 1 year was demonstrated in 
favor of endovascular coiling. The overall procedure-
related morbidity was 9–10% and mortality for endo-
vascular coiling was 1–2%. Procedural complications 
included aneurysm rupture (2–5%), symptomatic 
thromboembolic events (5–9%), parent vessel occlu-
sion (2.5%) and coil migration (0.5%). All the data 
suggested that endovascular coiling is better than 
surgical clipping for the treatment of cerebral aneu-
rysms, though the turf war is still ongoing.
Aneurysm occlusion relates to the size of the aneu-
rysm and its neck. Larger aneurysms with wide necks 
are more difficult to occlude completely. In ISAT [2], 
66% of aneurysms were completely occluded at follow-
up, 26% were subtotally occluded (neck remnant), 
and 8% were incompletely occluded. However, most 
aneurysms bleed from the dome or body and only 2% 
from the neck, and it seems logical that a small stable 
neck remnant is safe. Neurosurgical clipping does not 
guarantee occlusion [2,3]. Post-clip angiography shows 
that 4% of aneurysms are completely unclipped and 
another 4% show major remnants. With the use of 
early endovascular coiling, the rate of angiographic 
obliteration was significantly lower for aneurysms with 
a fundus-to-neck ratio of less than 2 [4–6]. This led 
to the development of balloon-assisted coil emboli-
zation techniques that were successful in swine an-
eurysm models as early as 1994. Moret et al [7] and 
others [8–11] have described the clinical use of this 
technique in humans, and have achieved excellent ob-
literation rates for wide-neck aneurysms with balloon-
assisted coil embolization. However, this technique is 
associated with an increased risk of thromboembolic 
events as high as 18% [12] and a higher risk of hemor-
rhagic complications because of increased pressure 
at the aneurysm neck with balloon inflation [8]. The 
development of a self-expanding flexible stent de-
signed to navigate the tortuous intracranial vasculature 
has revolutionized endovascular management of wide 
neck aneurysms. The Neuroform stent is a nitinol stent 
delivered over a guidewire enclosed within a micro-
catheter that expands with limited radial force on the 
vessel. Data [13,14] with the first-generation Neuroform 
stent demonstrated complete occlusion in 73% of 
patients and a complication rate of 10.7%, mainly in-
volving thromboembolic events. Other centers [15,16] 
have demonstrated similar results with improved tech-
nical stent success and delivery with a newer design, 
whereas procedural morbidity and mortality remains 
at 11%. Another problem with the stent-assisted 
method is the risk of thromboembolic events and 
the potential for long-term development of in-stent 
stenosis [17].
Aneurysm recanalization may occur because the 
aneurysm lumen is only partially filled with coils. 
According to an experiment, a completely occluded 
aneurysm contains 25–35% of its volume in coils; the 
rest is thrombus. The body’s natural thrombolytic pro-
cesses and coil compaction, more likely in a wide neck, 
may cause this recanalization and it is estimated that 
about 10% of coiled aneurysms will require a second
treatment to ensure stability. The risk of rebleeding 
has been documented to be 0.2% per patient-year with 
a follow-up of 1 to 8 years (mean, 4) [2]. This is similar 
to the rebleeding rate after neurosurgical clipping.
To achieve safer, more durable treatment, and 
less coil compaction and recanalization of aneurysms 
after coiling, several modifications to the bare plati-
num coils have increased the formation of thrombus 
within the aneurysm, thus reducing risk of recanali-
zation. They include bioactive coils, hydrogel coils and 
radioactive coils. The bioactive coils, such as Matrix 
coil (Boston Scientific), are coated with polyglycolic-
polylactic acid to enhance thrombus formation and 
organization, and accelerate aneurysm fibrosis and 
neointima formation with increased neck tissue thick-
ness but no parent artery stenosis [18,19]. The hydro-
gel coils are platinum coils coated with a polymeric 
hydrogel that swells when in contact with blood. They 
occupy more space by increasing coil volume from 
threefold to ninefold within the aneurysm, and achieve 
greater packing density to reduce recurrence rates 
and also stimulate a healing cellular response. The ra-
dioactive coils are implanted with P-32 emitting beta 
radiation and the local beta emission can prevent 
recanalization, probably by increasing neointima for-
mation and other unknown mechanisms. Early data 
involving the hydrogel coil and the Matrix coil sug-
gest equivalent or inferior periprocedural outcomes 
and recanalization rates, respectively [20–22]. Some 
trials are underway or are being designed to test the 
efficacy of some of these developments. The future 
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of bioactive endovascular technology will likely involve 
delivery of growth factors, including vascular endothe-
lial growth factor, transforming growth factor-β and 
fibroblast growth factor, as well as gene therapy or 
cellular substrates within the aneurysm that will re-
generate or remodel an endothelial wall layer across 
the aneurysm neck.
Final techniques for treatment of aneurysms de-
pend on the experience of the neurosurgeons and 
neurointerventionalists at each center. In the treat-
ment of unruptured intracranial aneurysms, there is 
still more controversy. The main patient and aneurysm 
risk factors for rupture of intracranial aneurysms are 
older age, female gender, larger size, location of the 
aneurysm at the posterior circulation and symptoms 
caused by the aneurysm. If there are no contraindi-
cations and patients have no serious preexisting 
diseases, treatment should be considered for all un-
ruptured aneurysms in patients aged < 50 to 60 years 
(open surgery), as well as perhaps for aneurysms of 
> 7 mm in diameter in older patients. Patients with 
symptomatic aneurysms should be candidates for 
treatment irrespective of age and symptoms.
3. Cerebral arteriovenous 
malformations (AVM)
Therapeutic options for cerebral AVMs include neuro-
surgery, embolization and stereotactic radiosurgery, 
in any combination, or no treatment at all if the risks 
of treatment are considered worse than the natural 
history. The aim of treatment usually is to obliterate 
the AVM completely, to eliminate the risk of hemor-
rhage and, less frequently, to reduce the effects of steal 
or venous congestion. The most critical step in the 
successful management of any patient’s AVM is the 
formulation of a treatment strategy designed to opti-
mize the risk-to-benefit ratio. This is predicated with 
an understanding of the natural history of the lesion, 
as well as the morbidity and mortality associated with 
various treatments. The overall lifetime risk of hem-
orrhage is estimated at 40–42% [23,24]. Having said 
that, most estimates approximate a 2–4% per year risk 
of hemorrhage [23,25]. In the year immediately after 
a symptomatic hemorrhage, the rebleeding risk is gen-
erally thought to be considerably higher, in the order 
of 6–18% per year, gradually returning toward the 
2–4% baseline with time [25–28]. AVM-related factors 
re presenting a higher or high bleeding risk, such as 
previous hemorrhage, intranidal aneurysms and singu-
lar or even impaired venous drainage, will have high 
priority.
For the resection of Grade I and II AVMs (< 1%), and 
Grade III AVMs (< 3%), the morbidity and mortality 
rates are subjectively very low in neurosurgical treat-
ment. However, much higher morbidity rates were 
observed for Grade IV and V AVMs, reaching 31% and 
50%, respectively, in the early postoperative period. 
They subsequently improved to 22% and 17%, respec-
tively, at the time of the follow-up examination [29,30]. 
Since the surgical resection of Grade IV and V AVMs is 
generally associated with a risk of operative morbidity 
and mortality, and there is a relatively low risk of hem-
orrhage in these patients (1% per year) [31], no treat-
ment for most patients in this group is advised.
The goals of preoperative embolization may be to 
generally reduce the degree of arteriovenous shunting 
and total blood flow through the nidus, in an effort to 
reduce blood loss during surgical excision. Alternatively, 
the goal may be more directive, such as embolizing the 
deep feeders to obliterate the section of the AVM 
that is more difficult to resect. Jafar et al [32] demon-
strated that preoperative embolization reduced the 
operative morbidity of large AVMs to a level similar to 
that of smaller AVMs that were not embolized before 
surgery. DeMeritt et al [33] reported similar results with 
preoperative embolization of large AVMs, reporting 
improved postsurgical outcomes in comparison with 
a control group of smaller AVMs that were not emboli-
zed. However, in patients with Grade IV and V AVMs 
after partial treatment, Han et al [31] observed a hem-
orrhage rate of 10.4%, compared with a 1% risk in 
patients with no previous treatment. Another report 
[34] found an annual risk of hemorrhage of 14.6% in 
patients who underwent palliative treatment of cere-
bral AVMs. Wikholm et al [35] observed an increased 
rate of hemorrhage and death in patients undergoing 
partial treatment that resulted in less than 90% nidus 
obliteration. When an unresectable AVM hemorrhages 
one or more times, targeted partial treatment with en-
dovascular exploration for an intranidal aneurysm and 
other risk factors, to reduce the risk of bleeding or to 
reduce the effects of steal, represents a reasonable 
strategy. Although the reported rates of complete en-
dovascular obliteration of cerebral AVMs vary, most 
series estimates are in the range of 10% [36–40], 
though some have achieved 22% [41] and 40% [42].
Currently, N-butyl cyanoacrylate (NBCA) is the choice 
for AVM embolization. NBCA is radiolucent and must 
be mixed with a radio-opaque agent, typically ethio-
dized oil (e.g. lipiodol, ethiodol) in a 1.5:1 to 3:1 (oil-to-
NBCA) mixture for most applications. After so lidifying,
the cyanoacrylates (if a sufficient volume has been 
injected) create an immediate occlusion of the emboli-
zed pedicle.
Onyx (EVOH copolymer-DMSO solvent) is mechan-
ically occlusive but nonadhesive, inert and less inflam-
matory than NBCA, soft and compressible, easier to 
operate, more controllable and more predictable, and 
allows better surgical handling. Very slow controlled 
injections allow permeation of the Onyx through the 
various AVM compartments via interconnecting vas-
cular channels. Tantalum powder must be mixed with 
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the agent to provide radio-opacity. Jahan et al [43] re-
ported no recanalization in a small number of patients 
imaged up to 20 months after embolization. Murayama 
et al [44] demonstrated no recanalization in swine after 
6 months of follow-up. Long-term follow-up is neces-
sary to prove that Onyx is a better embolic material 
for cerebral AVM.
The complication rates of AVM embolization vary 
from 3% to 35% and are obviously higher for higher 
grade AVMs, which may require multiple embolizations 
and are located in or close to eloquent cortex. Many 
are transient, but minor permanent deficits occur in 
10% and major in 8%, and mortality is around 1–2% 
[24,37,38,40,45–47]. Complications may be throm-
boembolic or relate to venous occlusion, arterial per-
foration or pressure breakthrough bleeding.
In Taiwan, stereotactic radiosurgery is very popular 
for the treatment of cerebral AVMs. In our institute, 
we consider that radiosurgery should be applied to 
AVMs in patients with no evidence of previous bleed-
ing at the location of eloquent or deep-seated regions, 
with the longest diameter less than 3 cm or the whole 
volume less than 27 mL. Though there are many pa-
pers that mention that size is of no matter in radiosur-
gery, the total obliteration rate is definitely decreased 
as size increases. We combine embolization with radio-
surgery for the purpose of reducing the volume of 
the AVM, and eradicating the dural supply and AV 
shunting inside the nidus, which are resistant to ra-
diotherapy. So far, there have been no large series 
reports about the outcome of combination treatment 
of embolization and radiosurgery for brain AVMs.
4. Direct carotid cavernous fistulae (CCF)
Direct CCFs may be spontaneous or acquired lesions. 
The most common clinical signs include cavernous 
cranial nerve palsies, proptosis, chemosis, pain and 
reduced visual acuity. Retinal perfusion pressure can 
be compromised to the extent of inducing permanent 
blindness [48]. Usually, the aim is to preserve the in-
ternal carotid artery (ICA), so using transarterial bal-
loon embolization with detachable balloons passed 
through the fistula and into the cavernous sinus to 
occlude the tear in the ICA is the first choice of treat-
ment. If transarterial balloon occlusion is not feasible, 
transvenous embolization may be performed using 
a microcatheter positioned in the cavernous sinus 
via the inferior petrosal sinus. Even when the inferior 
petrosal sinus cannot be visualized angiographically, 
a channel can usually be found by probing with a steer-
able guidewire in up to 75% of cases [49–52]. The 
embolic material can be a balloon, coils or even NBCA, 
depending on different scenarios. Recently, there have 
been reports of placing a covered stent across the fis-
tula and/or stent-assisted coil embolization [53–56]. 
The outcome of management of direct CCFs is usually 
excellent [57,58]. The patient’s proptosis rapidly re-
gresses and the eye may be completely normal 1 week 
later. Visual acuity and ophthalmoplegia may take 
longer to resolve, and can be exacerbated in the short-
term by thrombosis and associated swelling within the 
cavernous sinus [59]. In a review of 87 patients with 
direct CCFs, detachable balloon embolization allowed 
ICA preservation: during the mean follow-up period of 
10 years, diplopia improved in all patients and there 
was no recurrence of bruit, chemosis, proptosis or 
conjunctival edema [57].
5. Dural arteriovenous fistulae (DAVF)
DAVFs are acquired lesions, thought to originate from 
an insult to a dural venous sinus that stimulates an 
inflammatory response with subsequent neovascu-
larization, angiogenesis and development of patholog-
ical shunts at the arteriolar level. The initial insult may 
be thrombophlebitis, trauma, intracranial surgery or 
dural venous thrombosis. Alternatively, the fistula 
could be the initial event, with turbulent arterialized 
blood flow in the dural venous sinus inciting a process 
of thrombosis, stenosis and occlusion [60].
The most common presentation is in perimenopau-
sal women and is least common in men (27%), sug-
gesting an underlying hormonal influence [61–64]. The 
transverse and sigmoid sinuses are most commonly 
in volved, followed by the cavernous sinus, the latter 
also referred to as indirect cavernous sinus dural arte-
riovenous fistulae (CSDAVF). In Asian countries, includ-
ing Taiwan, Japan and Korea, the incidence of CSDAVF 
seems to be higher than elsewhere. In our in stitute,
CSDAVF constitute about 45% of all DAVF, followed 
by DAVF in the transverse and sigmoid sinus (35%).
Some authors believe that the pathophysiological 
changes of persistent arteriovenous fistulae result in 
venous stenoses and sinus occlusions that develop 
in cases of low-risk fistulae, which then can transform 
into higher risk lesions. Any change in the patient’s 
symptoms, such as worsening headaches or change 
in the quality of pulsatile tinnitus, may indicate alter-
ation in the venous drainage pattern and risk of hem-
orrhage [65]. In our experience, this is extremely rare 
in CSDAVF but can occur in other DAVF.
The classification that was proposed by Merland 
et al [66] is perhaps the most widely accepted among 
the various classification systems for DAVF. This clas-
sification indicates that the risk of intracranial hem-
orrhage is related to the venous drainage pattern. 
Low-risk fistulae exhibit antegrade venous drainage 
into a venous sinus, whereas high-risk fistulae exhibit 
reflux into a cortical vein(s) from the dural venous 
sinus or direct drainage into a cortical vein when the 
adjacent sinus is occluded. The cortical veins develop 
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tortuosity, stenoses and venous aneurysms that are 
potential sites of hemorrhage. Cognard et al’s classi-
fication [67] is a modification of Merland et al’s clas-
sification and also useful in risk assessment. Cognard 
et al classify five main types of venous drainage in 
DAVF: type I includes DAVF that drain into a sinus with 
normal antegrade flow; type II DAVF drain into a sinus 
but there is insufficient antegrade flow because of 
sinus stenosis/occlusion or high flow and there is re-
flux into either venous sinuses (IIa), cortical veins (IIb) 
or both (IIa + b); type III fistulae drain into cortical 
veins without venous distension; type IV fistulae drain 
into cortical veins with venous ectasia; type V fistulae 
drain into spinal perimedullary veins. Some may add 
a type VI that drain into bilateral cerebral hemispheres 
with stasis of venous ectasia.
In patients with low-risk fistulae (usually types I 
and IIa), the lesions may be discovered incidentally 
during angiography, or present with pulsatile tinnitus 
chemosis or headache. Spontaneous resolution of 
angiographically-proven DAVF has been reported to 
occur in 5–10% of cases. Aggressive features are pres-
ent in about 37% of type IIa and these relate to ele-
vated intracranial pressure. Patients with type I or 
type IIa DAVF are not at risk from ICH [67]. For type I 
lesions, conservative treatment, carotid-jugular com-
pression or particulate transarterial embolization will 
usually relieve the symptoms. The treatment of choice 
for type IIa is arterial embolization of the external 
carotid artery (ECA) feeders using polyvinyl alcohol 
(PVA) particles, repeated as necessary to diminish flow 
and intracranial hypertension. However, this achieves 
angiographic cure in only a small number; recanali-
zation occurs and there is often recruitment of other 
feeding arteries.
High-risk fistulae (other than types I and IIa) may 
present with hemorrhage into the subarachnoid space 
or brain parenchyma resulting in focal neurological 
deficits or death. In those with type IIb fistulae, 30% 
have aggressive symptoms, with ICH and intracranial 
hypertension. In type IIa + b, aggressive features are 
present in two-thirds, in three-quarters of type III and 
nearly all of type IV. Half of those with perimedullary 
venous drainage have progressive myelopathy and 
most of the others have subarachnoid hemorrhage 
(SAH). Cortical venous drainage associated with ve-
nous hypertension is a well-known cause of neurolog-
ical deficit and severe headache [68]. In type VI, 
patients usually present with dementia or severe neu-
rological deficits. The outcome is usually poor but oc-
casional case reports with good outcomes have been 
noted. High-risk DAVF, therefore, warrant aggressive 
therapy, either endovascular or surgical, whereas low-
risk fistulae can undergo palliative treatment if symp-
toms, such as pulsatile tinnitus, are troublesome [67].
For CSDAVF, carotid-jugular compression can be 
performed in those cases incidentally found or in 
patients who refuse aggressive treatment. Carotid-
jugular compression involves compression of the ipsi-
lateral common carotid artery with the contralateral 
hand for 10 seconds per compression, 4–6 times each 
waking hour. The compression time may be gradu-
ally increased to 30 seconds, with the neck moder-
ately hyperextended to allow adequate compression, 
and performed for 4–6 weeks. This procedure should 
be supervised at first by a clinician to ensure that 
the patient does not experience a vasovagal attack 
or cerebral ischemia. If properly performed, it causes 
simultaneous compression of both the carotid artery 
and internal jugular vein, so reducing arterial flow and 
raising venous pressure. Cure may be achievable in 
approximately 34% of patients [69]. This form of 
treat ment is contraindicated in patients with carotid 
artery atherosclerosis, for fear of embolic events, 
those with hypercoagulable states and patients with 
cortical venous drainage, ICH or visual deterioration 
in whom more aggressive treatment is indicated. In 
low-flow CSDAVF (type B), presentation is less acute, 
and signs and symptoms may be both nonspecific 
and subtle. The patient may complain of retro-orbital 
headaches due to stretching of the dural lining of the 
distended cavernous sinus, or spontaneous throm-
bosis at the fistula site or draining veins. Most type B 
CSDAVF are associated with low morbidity and up to 
50% may spontaneously resolve [70]. Since they do 
not usually produce major neurological deficits and 
are not life-threatening, a minimally invasive form of 
therapy is desirable. Treatment should be focused 
on the patient’s symptoms and not necessarily 
complete angiographic cure.
ECA feeders may be embolized, preferentially using 
PVA particles (> 120 microns), achieving complete cure 
in 70–78% and improvement in 20–30%, with a com-
plication rate of 5% [71–73]. Recanalization, however, 
may occur and in these cases repeated transarterial 
particulate embolization or transvenous coil occlu-
sion of the cavernous sinus, either through the jugular 
vein and inferior petrosal sinus or through the superior 
ophthalmic vein, is indicated if the condition persists 
or deteriorates. Transvenous coil occlusion of the 
cavernous sinus achieves cure in most patients, with 
a 6% complication rate.
In transvenous embolization of DAVF in other lo-
cations, coils are deposited at the site of arteriovenous 
shunting. If this is possible, it can result in cure with-
out having to involve the myriad of feeding arteries. 
When transvenous access is prevented by occlusion 
of the recipient venous sinus, the site of shunting can 
be occasionally accessed transarterially or via a cor-
tical draining vein. The venous approach includes: 
transcranial embolization after limited craniotomy and 
direct venous sinus catheterization [74]; direct punc-
ture through the superior orbital fissure [75]; trans-
venous access to the cavernous sinus via the facial 
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and superficial temporal veins [76]. Although detach-
able coils have the advantage of being able to be re-
positioned or removed if placement is unsatisfactory, 
they are significantly more expensive and less throm-
bogenic than pushable fibered coils. A combination of 
the two types may be placed as a compromise. If the 
sinus is thrombosed on both sides of the DAVF, then 
there are a few options besides surgical operation and 
access may be gained either through the thrombosed 
portion [77], directly into the isolated portion of the 
sinus via a small craniotomy [78] or by careful transar-
terial embolization with low concentration NBCA [79].
Types III and IV are very aggressive, and partial 
obliteration will not adequately protect against hem-
orrhage. The goal of treatment must be complete oc-
clusion. In cases where the DAVF drains into a cortical 
vein, endovascular occlusion of the draining vein itself 
using coils may occlude the fistula preserving dural 
sinuses.
Chemosis and proptosis typically improve rapidly 
after successful obliteration of CSDAVF. Visual acuity 
and ophthalmoplegia may take longer to resolve and 
can be exacerbated in the short-term by thrombosis 
and associated swelling within the cavernous sinus 
[59]. In a retrospective review of 135 patients with in-
direct endovascularly-treated CSDAVF, 121 (90%) pa-
tients were clinically cured after a mean follow-up 
period of 56 months, and a good clinical recovery 
(modified Rankin Scale score of 1–2) was demon-
strated in more than 97% of the population at long-
term follow-up examination [80]. In nine patients in 
whom transvenous coil embolization was performed 
for CSDAVF, two patients suffered temporary deterio-
ration of ocular motor function [81]. There is some 
evidence that this effect may be limited by the use of 
corticosteroid agents or heparin in the postoperative 
period [82]. In a recent study of 135 patients in whom 
endovascular treatment was conducted for intracranial 
DAVF, cure was achieved in 74 patients and significant 
improvement in 54 [83]. In another series of 11 pa-
tients with DAVF of the transverse and sigmoid sinuses, 
preoperative transarterial embolization was undertaken 
in seven patients. Endovascular cure was achieved in 
one of four patients who underwent transvenous em-
bolization, and AV communication was significantly 
reduced in the remaining three patients [51].
6. Intracranial atherosclerosis
For patients with transient ischemic attack (TIA) or 
stroke due to intracranial atherosclerosis and who 
require medical treatment, the question remains as 
to what constitutes the best regimen. There have 
been many trials but all have failed to demonstrate 
that medication is the best choice for prevention of 
TIA or stroke in intracranial atherosclerosis. Both the 
Management of Atherothrombosis with Clopidogrel 
in High-risk Patients trial and the recent Clopidogrel 
for High Atherothrombotic Risk and Ischemic 
Stabilization, Management and Avoidance trial have 
demonstrated no benefits from the combination of 
aspirin and clopidogrel, and an associated increase 
in the risk of bleeding [84,85]. The European Stroke 
Prevention Study demonstrated the efficacy of dipy-
ridamole plus aspirin versus aspirin alone [85]. The 
Clopidogrel versus Aspirin in Patients at Risk of 
Ischaemic Events trial demonstrated a slight benefit 
for clopidogrel compared to aspirin [86]. Certainly, 
on the basis of the Warfarin-Aspirin Symptomatic 
Intracranial Disease study results, warfarin is not 
better than aspirin and there is an associated increase 
in the risk of bleeding too [87]. Judicious use of high-
dose aspirin, clopidogrel or dipyridamole as a single 
agent is likely the best first choice for conservative 
management in the context of global risk-factor re-
duction, including smoking cessation, cholesterol-
lowering agents, and diabetes and hypertension 
management.
For those patients who failed to respond to ag-
gressive medical treatment, the incidence of recur-
rent stroke was as high as 50% in the Stanford study. 
Most of the studies on angio plasty were small and 
results are not convincing when compared with the 
natural history of this disease. The results of intra-
cranial angioplasty and stenting performed between 
1999 and 2002 were reported in 10 series consist-
ing of 89 patients [88]. Technical success rates rang-
ing from 64% to 100% were reported, with major 
complication rates ranging from 0% to 36%. Recently, 
three clinical series on intracranial stenting have been 
reported. They are the Stenting of Symptomatic 
Atherosclerotic Lesions in the Vertebral or Intra-
cranial Arteries (SSYLVIA) study [89], the consecu-
tive series of angioplasty and stenting for M1 stenoses 
reported by Jiang et al [90], and the HDE (Human
Devices Exemption) Wingspan study [91]; all are im-
portant additions to the literature. The first two studies 
used balloon-expanding stents, while the Wingspan 
study used self-expandable stents. The perioperative 
mobility rate, mortality rate and 12-month stroke rate 
demonstrated that the Wingspan system seems to 
have a better safety profile and lower restenosis rate 
than other systems to date. Since these reports have 
taken place within 3 years, long-term results are not 
yet available. From our own limited experience, within 
3 years, no patient was found to have symptom atic 
restenosis in a series of 32 patients, and about 25% 
of patients have asymptomatic stenosis (< 50%) either 
inside the stent or at the margin of the stent.
Since intracranial stenting is a high-risk procedure, 
we selected patients who have failed to improve with 
aggressive medical treatment for 3 months and have 
poor cerebrovascular reserve capacity. According to 
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the experience from coronary arteries, drug-eluting 
stents have more in-stent stenosis and the problems 
with the balloon-expandable bare stents are the same: 
the study on such stents was very small.
7. Acute symptomatic intracranial 
arterial occlusion
Intravenous (IV) recombinant tissue plasminogen ac-
tivator (rt-PA), given to selected patients within 3 hours 
of ictus, remains the only approved treatment for 
acute symptomatic intracranial arterial occlusion [92]. 
Unfortunately, less than 5% of the eligible population 
receives this treatment in most countries. Additionally, 
strict adherence to this time window precludes many 
patients who might benefit from thrombolytic treat-
ment and includes those who are unlikely to benefit. 
For example, those with internal carotid artery and 
main trunk middle cerebral artery (MCA) (M1) occlu-
sions (if a proximal artery is occluded, insufficient IV 
drug reaches the thrombus), and those in whom the 
embolus has already dissipated (20–25%). Despite this 
advance in treatment, results with IV thrombolysis re-
main suboptimal and several randomized studies have 
failed to demonstrate significant benefits [93–99]. 
More recently, intra-arterial (IA) thrombolysis has been 
found to be safe and effective for the treatment of 
acute, anterior-circulation occlusion if instituted within 
6 hours of symptom onset [100,101]. Nevertheless, 
reocclusion has been found to occur relatively fre-
quently during IA thrombolysis for ischemic stroke and 
seems to be associated with poor clinical outcomes 
[102,103]. Currently, accepted therapies for patients 
with contraindications for IV thrombolysis or occlusive 
lesions refractory to thrombolytic therapy include a 
combination of IA pharmacological thrombolysis and/
or mechanical thrombolysis.
IA thrombolysis involves the direct infusion of the 
thrombolytic into the occluding thrombus, achieving 
higher local concentration of the drug, lower systemic 
concentration and fewer extracranial hemorrhagic 
complications. Faster and more complete recanaliza-
tion may be achieved, particularly with proximal MCA 
occlusions. This allows a longer time window of 3–6 
hours or longer if perfusion studies are favorable. 
Cerebral angiography allows direct visualization of the 
occluding thrombus and directly monitors thrombus 
dissolution.
Additionally, mechanical means may also be applied 
to disrupt the clot using the micro-guidewire and this 
may facilitate the action of the thrombolytic agent. 
Clot retrieval devices are now available that may actu-
ally extract the thrombus from the occluded artery, 
achieving reperfusion much more readily. Mechanical 
thrombolysis is obviously invaluable if the clot is 
resistant to IA rt-PA. The recently Food and Drug 
Administration (FDA)-approved Merci retriever throm-
bectomy device (Concentric Medical Inc., Mountain 
View, CA, USA) and stent-assisted recanalization are 
steps toward the future [104–111]. Pharmacological 
IA thrombolysis fails to recanalize vessels in approxi-
mately 50% of patients [109,112,113]. This is largely 
attributable to underlying atherosclerotic disease and 
“hard clot” [100,101]. Part I of the Mechanical Embolus 
Removal in Cerebral Ischemia (MERCI) trial was com-
pleted in 2004. It demonstrated Thrombolysis in 
Myocardial Infarction/Thrombolysis in Cerebral 
Infarction (TIMI/TICI) Grade 2 or 3 flow in 12 out of 
28 (43%) patients treated with the retriever alone and 
in 18 out of 28 patients (64%) treated with the retriever 
plus additional IA t-PA [105]. The results of both parts 
of this trial [111] documented recanalization rates of 
33% without thrombolytics versus 51% with additional 
thrombolytics. Another study done with the Merci de-
vice (L5) consisted of patients ineligible for IV t-PA or 
those in whom recanalization had failed after IV t-PA 
thrombolysis [114]. In this study, subsequent passes 
could be made with the Merci device. Adjuvant ther-
apy with IA t-PA was allowed after attempts had been 
made with the retriever. Successful recanalization after 
Merci retriever use was obtained in 60 out of 111 
(54%) treatable vessels and successful recanalization 
was achieved after adjunctive therapy (IA t-PA, me-
chanical) in 77 out of 111 (69%) treatable vessels. 
Clinically significant procedural complications oc-
curred in 11 out of 111 (9.9%) cases. The rate of 
symptomatic ICH was 9.0% (10 out of 111) overall. 
Good neurological outcome (modified Rankin scale 
score of ≤ 2) was achieved in 32% of the population 
treated.
Stenting is an appealing alternative that has been 
useful in achieving recanalization in acute intracra-
nial vessel occlusion. Self-expanding and balloon-
mounted stent-assisted recanalization of embolic 
occlusions has been tested in vivo in a canine model 
[115]. Recanalization of 90% of vessels acutely oc-
cluded with either soft or hard clot was achieved. 
Buttressing of the clot by the stent is likely to be the 
main mechanism involved. A clinical study done on 
intracranial stent implantation with coronary balloon-
expandable stents after failed pharmacological and/
or mechanical thrombolysis found reestablished flow 
(TICI 2 or 3) in medium or large intracranial vessels in 
15 out of 19 (79%, excluding T-lesions) patients in 
whom no other therapeutic options were available. 
Self-expandable stent implantation also seems to have 
potential, as shown in recent reports [104,110,116].
Another mechanical thrombolysis trial used ultra-
sound. In the phase II Combined Lysis of Thrombus 
in Brain Ischemia Using Transcranial Ultrasound 
and Systemic t-PA trial, complete recanalization or 
substantially improved clinical condition was observed 
in 31 out of 63 (49%) patients in the ultrasound plus 
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IV t-PA group versus 19 out of 63 (30%) patients in 
the control group (t-PA only) [117].
In a recent report of IA therapy in 168 patients with 
acute stroke, the combination of IV GP IIb/IIIa inhibi-
tors and IA thrombolytics (t-PA or urokinase) in the 
setting of multimodal therapy was an independent pre-
dictor for recanalization of occluded vessels (p< 0.048) 
[106]. Many trials on IV plus IA chemical thrombolysis 
for the treatment of acute arterial occlusion are still 
ongoing.
Vertebrobasilar occlusion is usually associated 
with a poor prognosis, with overall mortality rates of 
70–80%. There are no randomized studies but many 
cases of thrombolysis have been reported in the liter-
ature using local IA infusions of urokinase or rt-PA 
[118]. Successful recanalization, either partial or com-
plete, has been achieved in 70% of cases over a me-
dian infusion time of 120 minutes, resulting in 
survival rates of 55–70%. Survival rates in untreated 
or persistent occlusion were 0–10%. All survivors in 
the untreated group were at least moderately disabled. 
Two-thirds of those treated aggressively had good 
outcomes. Distal occlusions are probably due to em-
boli and not surprisingly are easier to lyse than prox-
imal occlusions, which are more likely to be the result 
of a thrombus superimposed on an atherosclerotic 
plaque. The latter often requires adjuvant treatment 
with angioplasty and/or stenting. Paradoxically, these 
may have generated collaterals so the time window is 
extended. It seems to be that more aggressive treat-
ment to posterior circulation acute arterial occlusion 
is reasonable.
From an analysis [119] of the mortality and out-
comes of 1117 patients from 27 reports between 
1998 and 2006, reviewers found considerable vari-
ability and lack of evidence for a net improvement in 
outcome after IA therapy relative to predicted natural 
history, substantiating the need for a prospective 
comparison with best medical therapy. Better out-
comes were found in those reports related to: lower 
doses of urokinase; use of fixed dose thrombolytic 
without regard for success or extent of recanaliza-
tion; recanalization achieving better results than non-
recanalization. The MERCI mechanical thrombectomy 
trial was the eighth worst study among the 27 reports. 
The authors concluded that aggressive recanalization 
should not be the only goal of IA thrombolytic treat-
ment of acute ischemic stroke. For those patients who 
do not readily recanalize, more aggressive efforts may 
actually have had harmful effects.
In our institute, if a thrombus is superimposed upon 
a stenosis, it may be necessary to undertake angio-
plasty or stent the lesion. Mechanical thrombolysis 
may also be considered if pharmacological thrombol-
ysis is contraindicated. In the posterior circulation, 
we will extend the therapeutic window to 12 hours. 
Clearly, in all treatment options, prompt diagnosis and 
treatment are paramount to good outcomes. Advances 
in neuroimaging techniques have also improved the 
selection of candidates for acute stroke revasculari-
zation. Recently, we have used perfusion computed 
tomography (CT) and signal intensity CT angiography 
(CTA) for evaluation of penumbra. We shall use the 
concept of image-therapeutic-window instead of time-
therapeutic-window when we select a candidate for 
intracranial thrombolysis in the near future.
In conclusion, further development of better de-
vices, and new molecular and cellular regimens will 
be targets in the treatment of many neurovascular 
diseases. Interventional neuroradiology will play an 
important role in such treatment for its unique skill 
trained and the vast experience in treating different 
neurovascular diseases.
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